Immune responses against an introduced transgenic protein are a potential risk in many gene replacement strategies to treat genetic disease. We have developed a gene delivery approach for hemophilia B based on lentiviral expression of human factor IX in purified hematopoietic stem cells. In both normal C57Bl/6J and hemophilic 129/Sv recipient mice, we observed the production of therapeutic levels of human factor IX, persisting for at least a year with tolerance to human factor IX antigen. Secondary and tertiary recipients also demonstrate long-term production of therapeutic levels of human factor IX and tolerance, even at very low levels of donor chimerism. Furthermore, in hemophilic mice, partial functional correction of treated mice and phenotypic rescue is achieved. These data show the potential of a stem cell approach to gene delivery to tolerize recipients to a secreted foreign transgenic protein and, with appropriate modification, may be of use in developing treatments for other genetic disorders.
Introduction
X-linked hemophilia B is a bleeding disorder caused by the absence of the secreted blood coagulation factor IX (hFIX). A serious complication in hemophilia B treatment is the formation of inhibitory antibodies against the infused protein factor, occurring in approximately 2% of all hemophilia B patients 1-4 and 3-4% of severe hemophilia B patients 1, 3, 5 in most populations. Although some of these patients are treatable using various protocols to induce tolerance to hFIX, 5 there is a subset of patients who do not respond and are therefore at a high risk of anaphylaxis and life-threatening hemorrhagic complications. 6, 7 Any gene delivery strategy aimed at this subset of hFIX reactive patients must include a level of immune tolerance to the delivered transgene in order to attain successful long-term gene expression.
Hematopoietic cells are an attractive site for hFIX production, as they should permit release of the factor directly into the bloodstream. In addition, ex vivo gene delivery and re-implantation of syngeneic bone marrow (BM) limits direct exposure of patients to the gene transfer vector and is likely to be more scaleable than conventional in vivo gene delivery.
Previous work [8] [9] [10] has mainly focused on delivery of coagulation factor VIII (FVIII) to BM to treat hemophilia A. Given that both factor VIII and IX are secreted from the liver into the plasma where they are active in coagulation, a common delivery approach is likely to be applicable to both factors.
Interestingly, retroviral delivery of FVIII cDNA to whole BM explants in mice resulted in tolerance to FVIII in only 50% of recipients, while FVIII levels were undetectable by immunoassay. 8 Similar difficulties were also seen using a lentiviral vector to deliver FVIII cDNA to whole BM of C57BL/6J hemophilia A mice. 9 Modest levels of expression were observed, concomitant with high levels of inhibitory antibodies against the factor, suggesting that tolerance to the transgene was not attained. A recent study used a reduced conditioning regimen to deliver lentivirus-expressed FVIII cDNA to BM and therapeutic expression was observed for over 4 months. 10 It should be noted, however, that immuno-deficient B7-2 knockout mice were used to eliminate the potential problem of neutralizing antibodies to FVIII observed in the Kootstra study 9 -thus no assessment of tolerance to FVIII could be made.
The lack of tolerance in these studies could have been due to a lack or loss of gene expression, an insufficient level of BM transduction or a failure to express alloantigen on cell types capable of inducing tolerance, [11] [12] [13] [14] particularly since both FVIII and FIX are secreted antigens. We therefore decided to enrich for hematopoietic stem cells prior to transduction with a lentiviral vector expressing hFIX in order to eliminate these problems.
We demonstrate reliable long-term therapeutic levels of hFIX antigen (hFIX:Ag) in C57Bl/6J normal mice, phenotypic rescue of 129/Sv hemophilic mice and tolerance to hFIX:Ag in chimeric mice.
Results

Lentiviral-eGFP-transduced Lin
À BM cells have multilineage potential in normal recipient mice To achieve lentivirus gene transfer to hematopoietic stem cells (HSC) and to determine which cells expressed the delivered transgene, we firstly delivered a lentiviraleGFP vector (pHR'SIN-cPPT-SEW) at an MOI of 30 to a lineage depleted fraction (Lin À ) of mouse BM, enriched for hematopoietic stem cells. In this system, eGFP expression is controlled by the spleen focus forming virus (SFFV) promoter that has been previously shown to produce sustained expression in most cells of the hematopoietic system. 15 At 6 weeks after engraftment of 0.5-1.0 Â 10 5 eGFP-transduced Lin À cells in myeloablated recipients (n ¼ 16), we analysed the BM and spleen for eGFP expression. We found effective transduction of myeloid and lymphoid cell lineages with an average of 33.2% eGFP-expressing CD45 + cells in the BM and 31.2% in the spleen (Figure 1 hFIX production and tolerance in primary C57Bl/6J recipients of lentiviral-hFIX transduced HSC In order to establish the ability of a lentiviral vector to produce hFIX long-term in engrafted cells, and to determine immune responses to hFIX-expressing cells in C57Bl/6J mice, we transduced Lin À cells with a lentiviral-hFIX expressing vector (pHR'SIN-cPPT-S-FIX-W) also under the control of the SFFV promoter. Cells (2-5 Â 10 4 ) were transplanted into lethally irradiated C57Bl/6J recipients ( Figure 2 ) (D-K), along with control mice receiving untransduced cells (A-C).
Mice were shown by Q-PCR detection of the TSPY Y-linked gene to have 80-100% male donor chimerism in the spleen or BM of female recipients A, D, E, F and G (Figure 2a) , while in mice H, I, J, K, BM chimerism could not be determined as these were male to male transplants.
In all primary recipients, we demonstrate long-term therapeutic levels of hFIX:Ag production (Figure 2b) , lasting until the end of the study at 115-187 days. Six out of eight transplanted mice expressed hFIX:Ag levels of between 250 and 2450 ng/ml equivalent to a mild hemophilia phenotype in patients (250-2500 ng/ml). Mice I and J produced mildly therapeutic levels of hFIX:Ag of between 50 and 250 ng/ml for most of the study, putting them into the equivalent moderate category of hemophilia B in patients. Severe hemophilia is typified by plasma levels of hFIX:Ag o50 ng/ml in patients, while levels of 2500-5000 ng/ml (50-100% of normal) are regarded as phenotypically normal. No hFIX:Ag was detectable in control mice. Significant levels of anti-hFIX antibodies (41000 ng/ml) were not detected in any mice (Figure 2c) suggesting that tolerance or immunological unresponsiveness to the transgenic protein may have been achieved.
The lentiviral-hFIX vector was shown by Q-PCR detection of hFIX cDNA to be present in similar average copy numbers per haploid genome in B220 + , CD4/CD8 + cells, CD11c + (70-80% dendritic cells), peripheral blood, spleen and thymus, while whole BM or GR1 + cells often had higher relative copy numbers (Figure 2a) . The lowest average vector copy numbers detected in animals expressing hFIX:Ag at therapeutic levels for most of the study was 0.4 per haploid genome (animal I). However, considerably more vector copies (5-10) may be required to reliably maintain levels equivalent to a mild hemophilia phenotype (4250 ng/ml).
Sustained hFIX:Ag production and tolerance in secondary and tertiary C57Bl/6J recipients In order to examine whether long-term repopulating HSCs with self-renewal ability had been transduced with the lentiviral-hFIX vector, we performed secondary and tertiary transplantation experiments. Whole BM (1 Â 10 6 cells from D, E, F killed at 115 days) were injected into three myeloablated C57BL/6J recipients each (n ¼ 9), while a single recipient received 1 Â 10 6 whole BM cells from the control animal A (n ¼ 1). Two control animals received primary transplants of Lin À cells alone (C1 and C2) in an independent experiment. (Figure 3a ) showed suboptimal engraftment, with animal D2 being the most chimeric at 45%, while mice A1, D1, D3 and E2 had 6, 7, 3 and 1.6% donor-derived cells, respectively. In the case of F secondary recipients, chimerism was below 1%. This is close to the limit of copy number detection by the Q-PCR assay and probably indicates a total loss of male donor chimerism. The overall low levels of chimerism observed in secondary recipients may have been a result of the low cell numbers used for infusion. Q-PCR analysis of lentiviral-FIX vector copy number correlated with final hFIX:Ag levels and male chimerism in recipients (Figure 3a and b) . DNA from animals E1 and E3 was not available for analysis. In agreement with the measurements of hFIX relative to Q-PCR copy number, secondary recipients of D BM demonstrated therapeutic and persistent levels of hFIX:Ag up to at least 217 days post-transplantation, suggesting that these animals had been successfully repopulated with longterm repopulating HSCs expressing hFIX (Figure 3b ). Although mice repopulated by BM from animal F showed initial hFIX:Ag production at day 10 (509, 194, 116 ng/ml), these dropped below detectable levels by day 30. Secondary recipients receiving BM from animal E never showed any hFIX:Ag production. Both of these results are consistent with the minimal male donor chimerism detected in E and F recipients. The early hFIX production from F recipients is therefore likely to have come from committed donor cells that did not contribute to the engraftment process.
We challenged all remaining secondary recipients (D1, D3, E2, F3) with hFIX:Ag in adjuvant at days 189 and 206 ( Figure 3c , bottom scale) in order to investigate their tolerance status to the foreign transgenic protein.
Recipients of hFIX transduced HSC did not produce significant levels of inhibitory antibodies against hFIX: Ag (o1000 ng/ml) during the study, either before or after challenge, suggesting that these recipients are tolerant to hFIX. In order to ensure that the C57Bl/6J model was able to mount a normal immune response to hFIX:Ag, we also challenged control recipients of untransduced HSCs (C1, C2) in the same way at days 125 and 139 ( Figure 3c , top scale) and included untransplanted animals (U1, U2). A significant difference between controls (C1-2, U1-2) and challenged secondary recipients (D1, D3, E2, F3) was found at 22-38 days after the first challenge (Po0.01) (Figure 3c ), confirming that C57BL/6J mice were capable of mounting a significant humoral response to hFIX:Ag regardless of their transplantation status. Notably, although F recipients did not show donor reconstitution, as seen by rapidly decreasing hFIX:Ag levels and no significant chimerism at killing, they were still tolerant to hFIX:Ag; indicating that immunological unresponsiveness was attained at an early time point after BM transplantation.
We also performed tertiary engraftment experiments to further verify transduction of long-term repopulating HSCs. Total BM cells (1 Â 10 7 ) from D2 (killed on day 189) were used for tertiary engraftment into three myeloablated recipients. All recipients expressed therapeutic Plasma levels of hFIX:Ag were measured using ELISA. The shaded boxes represent the equivalent disease states in human hemophiliacs based on the normal plasma levels of hFIX (5000 ng/ml). (Severe phenotype: o50 ng/ml: white; moderate phenotype: 50-250 ng/ml: light shading; mild phenotype: 250-2500 ng/ml: dark shading.) (c) Serum levels of hFIX inhibitory antibodies were determined by ELISA throughout the course of the experiment, given in ng/ml.
Stem cell gene delivery to treat hemophilia B BW Bigger et al levels of hFIX:Ag until killing at 70 days after engraftment (168-388 ng/ml), while no anti-hFIX antibodies were detected (not shown). The long-term gene expression and tolerization in secondary and tertiary recipients with hFIX-expressing cells is indicative of successful transduction of long-term self-renewing HSCs.
hFIX:Ag production and tolerance in hemophilic mice is sustained for over a year
In order to confirm that tolerance to hFIX:Ag could be observed in other mouse strains, and to evaluate the functionality of hFIX in a transgenic setting, we engrafted 129/Sv hemophilic recipients (H1-9) with 1 Â 10 5 syngeneic BM-derived Lin À cells transduced with lentiviral-hFIX vector in two experiments (Figure 4 ). Control mice receiving untransduced (C1) or mocktransduced (C2) cells were also included. Q-PCR analysis of TSPY donor chimerism in the long-term studied animals (H1-7) showed an average donor engraftment of 81-100% in BM (Figure 4a ). Q-PCR analysis of the hFIX gene revealed the presence of 2-11 copies of lentiviralhFIX per haploid genome, roughly proportional to expression levels. As little as 1.2 copies were required to achieve therapeutic levels of expression (450 ng/ml), although like the C57Bl/6J mice, 5-10 copies are probably required to achieve sustained expression at levels above 250 ng/ml, the equivalent of a mild hemophilic phenotype.
All recipients receiving lentiviral-hFIX transduced cells produced hFIX:Ag for the duration of the study (Figure 4b ). Although there was some fluctuation in the levels of hFIX:Ag production, this is consistent with the kinetics of contribution of gene-marked cells in transplanted recipients. 16 Overall, hFIX:Ag levels remained relatively steady throughout the study for over a year, with only one animal (H2) bordering on subtherapeutic plasma hFIX:Ag levels (below 50 ng/ml) and one animal in the mild range of hemophilia for most of the study (250-2500 ng/ml) (H5).
In order to study the establishment of tolerance to hFIX in the 129/Sv hemophilic mice and to show that control 129/Sv hemophilic mice were also able to mount normal immune responses to hFIX, we performed two experiments to determine the types of response to hFIX (Figure 4c) . Firstly, the remaining animals that had received hFIX-transduced cells (H3, H5, H8, H9), untransduced (C1) or eGFP-transduced cells (C2) were challenged with hFIX:Ag at days 372 and 389 (bottom scale) and days 46 and 59 (top scale) and monitored for their levels of anti-hFIX antibodies. We further included seven age-matched untransplanted mice (C3-9) challenged at the same point to verify the antibody response to hFIX in this hemophilic mouse strain. A significant + dendritic cells from recipient D27s.d. (b) Plasma levels of hFIX:Ag were measured using ELISA. The shaded boxes represent the equivalent disease states in human hemophiliacs based on the normal levels of hFIX as given above. Human FIX challenges for remaining secondary recipients (D1, D3, E2, F3) (bottom scale) were given at days 189 and 206 (arrowed). Human FIX challenges for primary control recipients (C1, C2) were given at days 125 and 139 (top scale). Scales were standardized against the time of first challenge. (c) Graph showing the levels of anti-hFIX antibodies raised before and after identical challenges with hFIX in adjuvant in age-matched animals. These included secondary recipients of hFIX-transduced HSC (D1-F3), secondary transplant control (A1) (bottom scale), primary transplant controls receiving untransduced HSCs (top scale) (C1, C2) and untransplanted control animals challenged at the same time points as the primaries (U1, U2). A significant difference between controls (C1-2, U1-2) and challenged secondary recipients (D1, D3, E2, F3) was found at 22-38 days after the first challenge (Po0.01).
Stem cell gene delivery to treat hemophilia B BW Bigger et al difference between controls C1-9 and treated animals (H3, H5, H8, H9) was found at 21-31 days after the first challenge (Po0.003), clearly indicating that the 129/Sv strain is capable of mounting a normal humoral response to hFIX. In contrast, recipients receiving hFIX-transduced HSCs (H3, H5, H8, H9) did not produce significant levels of anti-hFIX antibodies (41000 ng/ml) at any point during the course of the experiment, suggesting that they had attained tolerance to the transgenic hFIX protein (Figure 4c ). In the second experiment, the T-cell response to hFIX was determined by measuring the proliferative capacity of splenocytes from challenged animals in response to hFIX (Figure 4d ). Cells isolated from two animals transplanted with hFIX-transduced HSCs (H3, H5) alongside splenocytes from an untransplanted, challenged animal (C3), a recipient of untransduced cells challenged with hFIX (C1) and splenocytes from an unchallenged control animal (C0) were incubated for 7 days in the presence of recombinant hFIX or concanavalin A. Cells from both challenged control animals (C1, C3) showed a small significant proliferative response to hFIX, in comparison to unstimulated cells (P40.05) while cells from an unchallenged animal did not (C0). Splenocytes of lentiviral-hFIX-transduced and challenged hemophilics H3 and H5 were not responsive to hFIX:Ag. Although 129/Sv mice do not mount a considerable cellular response to hFIX, the unresponsiveness of splenocytes from H3 and H5 to hFIX suggests that they are immunologically unresponsive.
Partial functional correction of hemophilic mice receiving hFIX-transduced HSCs
To assess the procoagulant function of hFIX in engrafted hemophilic mice, we performed one-stage FIX:C clotting assays on citrated plasma from engrafted hemophilic mice (sampled on days 97 and 147), in comparison with plasma samples from control (unengrafted) hemophilic mice and normal mice (Figure 5a ).
Clotting times for engrafted hemophilic mice were significantly shortened over control animals in both bleed 1 (Po0.01) and bleed 2 (Po0.001), although they were still prolonged compared to normal mouse plasma. (Figure 5a) ). (c) Graph showing the levels of anti-hFIX antibodies raised before and after identical challenges with hFIX in adjuvant. Unengrafted controls 1-7 were challenged at the same time as the others at 10 months old. A significant difference between controls C1-9 and treated animals (H3, H5, H8, H9) was found at 21-31 days after the first challenge (Po0.003). (d) Splenocyte proliferation assay 6-7 days after plating of cells, showing tritiated thymidine incorporation. Challenged control animals (C1, C3) exhibited a small but significant mitogenic response upon hFIX stimulation (Po0.05), whilst unchallenged control (C0) did not. Lentiviral-hFIX-engrafted animals H3 and H5 did not mount a response to hFIX, but all cells responded to the universal mitogen concanavalin A. Bars are 95% confidence intervals.
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Owing to excessive bleeding, only one of nine (11%) unengrafted hemophilic mice survived following bleed 1, whereas all engrafted hemophilic (6/6) and normal control mice (2/2) maintained normal hemostasis and survived (Figure 5b ). The tails of unengrafted hemophilic mice were cauterized after subsequent bleeds to ensure survival.
FIX:C assay clotting times are a direct reflection of FIX:C procoagulant activity, and in bleed 2 samples from engrafted animals, these were correlated with hFIX:Ag values ( Figure 5c ). As found previously, estimates of hFIX:C levels were higher than hFIX:Ag values when compared in human plasma units. 17 One engrafted animal with a low copy number (H2) showed both undetectable hFIX:C activity and low hFIX:Ag as detected by ELISA. The shorter clotting times of engrafted mice in the hFIX:C assay, the survival of all engrafted mice following bleed 1 and the correlation of hFIX:C with hFIX:Ag levels are indicative of phenotypic rescue of hemophilic mice.
In addition, correlations between lentiviral copy number and hFIX:Ag levels by ELISA at killing were established for both C57Bl/6J mice and 129/Sv hemophilic mice (Figure 5d ). These suggest that the minimal requirement for baseline therapeutic hFIX:Ag expression (450 ng/ml FIX:Ag) may be as little as 2-3 lentiviral copies per haploid genome.
Discussion
In this study, we have investigated the possibility of using a stem cell approach to correct hemophilia B by lentiviral delivery of hFIX to hematopoietic stem cells.
We were able to both transduce HSCs efficiently with a second-generation HIV-1-based lentiviral vector expressing eGFP and also observe eGFP production in all hematopoietic lineages with similar percentage efficiency in primary recipients. This is in agreement with ours and others data using lentiviral-eGFP for the transduction of human SCID repopulating cells 15, 18 and suggests that we have targeted at least short-term repopulating multilineage hematopoietic progenitor cells.
In both successfully engrafted normal and hemophilic mice, we observed therapeutic levels of hFIX:Ag in over 70% of lentiviral hFIX treated mice, lasting more than a year in primary recipients as well as long-term expression in secondary and tertiary recipients, demonstrating that we have transduced long-term self-renewing HSCs. Relatively high copy numbers of lentivirus vector (average 17.5 per haploid genome) were observed in the six primary C57BL/6J mice that achieved hFIX:Ag levels equivalent to a mild hemophiliac phenotype. We surmise that the differences in initial hFIX:Ag production in these animals, the fluctuations over time and the sudden marked increase in hFIX:Ag production in animals D and H are likely to be due to differences in the relative contribution of transduced and untransduced cells at engraftment and fluctuations in the expansion and contraction of transduced and untransduced HSC clones. Similar fluctuations have been observed in the relative contribution of transduced human HSC to hematopoiesis over time in NOD/SCID recipient mice 16 and the ability of an expanded clonal stem repopulating cell from a primary recipient to clonally repopulate secondary recipients. 19 We therefore believe that promoter or insertion site effects are only likely to have played a minor role in these fluctuations in hFIX:Ag as hFIX:Ag levels versus relative lentiviral copy number are roughly proportional in all animals at killing. In addition, we suggest that the minimal copy number required for baseline therapeutic gene expression 
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BW Bigger et al (450 ng/ml) is approximately two copies per haploid genome, a level that would serve to minimize the risk of insertional mutagenesis in these animals, although as many as 5-10 may be required to sustain levels at a mild hemophilia phenotype of 50-250 ng/ml. The variable level of hFIX:Ag production observed in secondary recipients can be shown by Q-PCR to be directly related to the low levels of male donor chimerism, could be the result of expansion of radioresistant recipient cells 20 and is unlikely to be due to poor lentiviral transduction or variable clonal expansion of donor cells. While 2 Â 10 4 syngeneic Lin À cells have been shown to be the lower limit for rescue of lethally irradiated mice, 21 increasing numbers of donor cells are required to successfully reconstitute recipients receiving sublethal doses of irradiation or those with increasing antigenic disparity. 20, 22, 23 When investigating immunological unresponsiveness to hFIX in the two animal models, we were aware that the C57Bl/6J 24 strain has been reported to have limited immune responses to hFIX:Ag delivered by adenovirus and that the 129/Sv strain has been shown to have a limited immune repertoire. 25 Although animals may not have mounted immune responses if challenged with hFIX alone, challenge with hFIX in adjuvant raised highly significant humoral and lower cellular responses against the antigen in control groups. Significant immune responses against hFIX have also been reported by others using these mouse strains. 24, 26 All recipients of hFIX HSC transplants exhibited strong evidence of tolerance to hFIX regardless of the levels of chimerism attained. The hFIX expression levels required to attain tolerance to the transgenic protein were quite low, in certain cases below the detection limits of our ELISA. We also provide evidence that transient production of hFIX was sufficient to induce unresponsiveness to hFIX:Ag in a subset of secondary transplant recipients that lost donor chimerism (F1-3) .
Previous studies by Evans et al. 8 delivering hFVIII to BM observed tolerance in only 50% of cases. Kootstra et al.
9 delivered hFVIII to BM using a lentiviral vector and observed the production of neutralizing antibodies to hFVIII. A combination of high transduction efficiency, high levels of donor chimerism, the lineage depletion of BM and the use of the long-term expressing SFFV promoter 15 may have been sufficient to overcome these problems in our case, although differences in the production or relative immunogenicity of FVIII versus FIX cannot be ruled out. It is known that delivery of recipient BM cells transduced with foreign MHC class I or II results in tolerance to the donor antigen. [11] [12] [13] [27] [28] [29] [30] Although hFIX is a secreted antigen and will be presented as a set of self-restricted peptides, the elimination of mature hFIX reactive T cells from the donor population by lineage depletion may give the hFIX-expressing donor cells sufficient advantage to establish hFIX-specific mixed cell chimerism. Approximately 30% eGFP chimerism was present in all recipients of eGFP transduced cells, although no assessment of tolerance was made. However, a study by Andersson et al. 31 has recently shown that eGFP-transduction of BM delivered to irradiated recipients results in tolerance to eGFP-expressing skin grafts.
Although our method of establishing therapeutic hFIX expression and specific tolerance utilizes myeloablation of recipients for repopulation, there are methods that may be employed to induce stable autologous/allogeneic states of mixed chimerism 32 that do not rely on myeloablative regimens. These include costimulatory blockade, 33 variants of T-cell depletion with thymic irradiation 34, 35 and coinjection of primed regulatory T cells, 36 which we are currently investigating. In addition, the use of O6-benzylguanine (BG)-resistant mutant O6-methylguanine-DNA methyltransferase (MGMT) or similar multi-drug resistance genes can be used for positive selection of transduced BM cells in the absence of myeloablation. 37 Notably, our technique demonstrates partial phenotypic correction in the absence of any cell or gene selective pressure and is achievable with clinically relevant numbers of autologous cells in immunocompetent individuals.
Direct delivery of hFIX cDNA to the liver, 26, 38 or the use of a liver-specific promoter in systemic delivery, 39 has been shown to be more successful in obtaining effective transgene expression, and at reducing inhibitor formation to hFIX particularly at the less immunogenic C57BL/6 strain. However, hFIX levels from our study are comparable to those attained by these delivery routes 26 ,38,39 and we have not seen evidence of immune responses against hFIX in either C57Bl/6J or 129/Sv treated mice despite significant antibody responses in control animals.
Although we did not investigate in detail the specific activity of hFIX, the phenotypic rescue of hemophilic mice obtained here suggests that hFIX produced by HSCs is functional in coagulation, and comparisons of estimated hFIX:C and hFIX:Ag values support this conclusion.
In summary, we have demonstrated efficient transduction of HSCs with our lentiviral vector, and determined the average copy number required to achieve therapeutic hFIX:Ag expression and phenotypic rescue of hemophilic mice. Moreover, we have shown that very low and transient levels of HSC microchimerism and hFIX production are sufficient to achieve tolerance to a delivered transgene in this system. We also show the ability to induce tolerance through the delivery of a secreted peptide to HSC that may prove to be important in many gene replacement strategies. Further investigation into the safety of lentiviral vectors and development of more effective nonmyeloablative BM transplantation regimens will be required before this protocol could be applied to disorders such as the hemophilias in a clinical setting.
Materials and methods
Lentiviral vector production
The lentiviral-eGFP vector based on HIV-1 expresses eGFP under control of the SFFV U3 enhancer region and was made as described (pHR'SIN-cPPT-SEW). 15 The pHR'SIN-cPPT-S-FIX-W vector (lentiviral-hFIX) was prepared as described previously, 17 while vector concentration and titration were also as described. 17 
HSC enrichment and transduction
Whole BM was isolated from tibias, femurs and pelvises of syngeneic animals and depleted of lineage-committed cells using antibodies against CD5, B220, GR1, CD11b, Stem cell gene delivery to treat hemophilia B BW Bigger et al Ter119, 7-4 in the Murine Progenitor Enrichment Cocktail (StemCell Technologies) as previously described. 18 The enriched hematopoietic stem cell fraction (Lin À ) was obtained using the StemSep (StemCell Technologies) immunomagnetic cell selection system according to manufacturer's recommendations. Purity was standardly 495%. Viral transduction of HSC was performed in X-VIVO-10 medium (BioWhittaker) without serum supplementation, containing murine SCF (Peprotech) and Flt3-Ligand (R&D Technologies), both at 50 ng/ml, and IL-6 (Peprotech) at 10 ng/ml. Lentiviral vectors carrying the eGFP or hFIX transgenes were added at an MOI of 30, over a 8-14 h culture period unless stated otherwise.
Animals
C57Bl/6J mice (Harlan, UK) were bred on site. 129/Sv hemophilia B mice with a disrupted FIX gene were obtained from Professor Inder Verma. 40 All animal work was carried out in accordance with UK Home office regulations and was compliant with the local ethical review committee. Mice were irradiated (2 Â 500 cGy in a divided dose, 4 h apart) and i.v. injected with 0.2-1 Â 10 5
Lin
À syngeneic BM cells or 2 Â 10 6 (secondary recipients) to 1 Â 10 7 (tertiary recipients) whole BM cells. For antigenic challenge, animals were injected first with 2 mg of hFIX (Cambridge Biosciences, UK) in 100 ml complete Freund's adjuvant, and secondly with 2 mg of hFIX in 100 ml incomplete Freund's adjuvant by subcutaneous injection approximately 13-18 days apart. The tails of prewarmed mice were cut with a scalpel to obtain free flowing blood for clotting assays. Cautery was necessary to ensure survival of hemophiliacs.
Genomic DNA preparation
Murine tissues were taken in RNAlater (Qiagen) and 20-50 mg used for DNA preparation 17 prior to resuspension in TE buffer or water.
Q-PCR
The hFIX or TSPY (Y-linked gene) copy number in DNA samples was analyzed by quantitative PCR analysis on an ABI Prism R 7700 sequence detector (Applied Biosystems). Primers for hFIX spanned exons 5 to 6; FIXfwd 5 0 -GCAGAAAACCAGAAGTCCTGTGAA-3 0 (900 nm) FIX rev 5 0 -CGGGTGAGCTTAGAAGTTTGTGAAA-3 0 (900 nm) and FIX probe 5 0 -6FAM CCAGCAGTGCCAT TTC-NFQ-3 0 (250 nm). Murine TSPY primers and probe were made as described previously. 41 This assay gave accurate TSPY chimerism assessment to at least 0.1% male DNA. Samples were standardized against a rodent GAPDH genomic primer/probe set (Applied Biosystems). All samples were analyzed in duplicate 25 ml reactions using the cycling parameters: 501C for 2 min, 951C for 10 min, followed by 40 cycles of 951C for 15 s and 601C for 1 min. Samples were calibrated against DNA from a cell clone with a known lentiviral-hFIX integration number according to the standard curve method of Applied Biosystems. Standard deviations represent the variance between repeat experiments. The detection limit in this assay is approximately 0.01 copies.
Flow cytometry
Animals receiving lentiviral transduced Lin
À cells were analyzed by antibody staining with rat anti-mouse CD45-CyChrome and either CD45R/B220-PE, CD19-PE, CD4-PE and CD8a-PE, CD11c-PE, CD11c-APC or Ly-6G/ Ly6C-PE antibodies (BD Biosciences). Live/dead staining was performed with propidium iodide or a 1/10 000 dilution of ToPro3 (Molecular Probes). FACS data were acquired on LSR (Becton Dickinson), cells sorted on FACS Vantage (Becton Dickinson) and flow cytometric analysis was performed using FlowJo software (Tree Star Inc.). FACS samples from transduced animals were normalized against BM and spleen from untransduced control animals by subtraction of the autofluorescent cells in the eGFP gate (typically 0.1-1%).
hFIX clotting activity (FIX:C) assay Citrated plasma samples (obtained by a tail tip sampling procedure) from normal, transduced and untransduced hemophilic mice were tested at 10-fold dilution in a onestage FIX:C clotting assay using human FIX-deficient plasma, as previously described. 17 Results are generally presented as direct clotting time comparisons since murine severe hemophilia B plasma gives apparent hFIX:C control values slightly above zero. 17 Estimates of hFIX:C levels were also made by use of a pooled normal human plasma reference.
Detection of hFIX:Ag and anti-hFIX antibodies
Plasma concentrations of hFIX:Ag protein were determined using the Asserachrom hFIX:Ag ELISA kit (Roche Diagnostics) as previously described. 17 Serial dilutions of hFIX supplied with the kit were used as an assay standard. It should be noted that previously reported hFIX levels 17, 42 should be two-fold higher than those presented. This is due to an error in the printed protocol supplied with the kit that has now been rectified by Roche.
Antibodies against hFIX were detected by ELISA; 96-well plates were coated at 41C overnight with 2.5 mg/ml hFIX and washed 5 Â with PBS/0.2% Tween 20. Serum samples were serially diluted in PBS/4% BSA (pH 8.1) along with a standard of mouse anti-human FIX (Dako, Ely, UK) and left overnight at 41C. Detection was with HRP-conjugated rabbit anti-mouse mAb (Dako) for 120 min at 41C. This antibody detects most immunoglobins (IgG1, IgG2a, IgG2b, IgG3, IgA and IgM.) After washing, o-phenylenediamine dihydrochloride/urea peroxide substrate solution (Dako) was added for exactly 3 min, and the reaction was stopped with 3 M sulfuric acid. Absorbances were measured at 450 nm. 
Splenocyte proliferation assay
Statistical analysis
Student's t-tests were performed between anti-hFIX antibody data sets grouped into controls or treated subsets at 12-15 days after the second challenge, between clotting times for treated versus hemophilic mice and also between splenocyte proliferation in response to hFIX versus normal where appropriate. Spearman's rank Stem cell gene delivery to treat hemophilia B BW Bigger et al correlation tests were performed on comparisons of clotting time versus hFIX levels and hFIX copy number versus hFIX levels. r measures the degree of linear relationship between two ranked variables, where 1 is a linear positive correlation, zero represents no correlation and À1 a linear negative correlation. P is the probability that a correlation has arien due to chance.
